NASDAQ$ABOS
Acumen Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results for the first quarter of 2023 and provided a business update.
Acumen Pharmaceuticals reported a net loss of $11.3 million for the first quarter of 2023. As of March 31, 2023, cash, cash equivalents and marketable securities totaled $183.8 million.
- Focused on executing the Phase I INTERCEPT-AD trial of ACU193.
- Expect to report topline results from INTERCEPT-AD in the third quarter of 2023.
- Cash, cash equivalents and marketable securities of $183.8 million as of March 31, 2023 expected to be sufficient to support clinical and operational activities through 2025.
- Presented research at the International Conference on Alzheimer’s and Parkinson’s Diseases (ADPD) in March 2023.
Headline financials
Revenue & EPS history
Acumen · Revenue · Quarterly
$0
Forward guidance
Acumen expects to report topline results from the Phase 1 INTERCEPT-AD trial in the third quarter of 2023 and anticipates interaction with the FDA in the fourth quarter to inform the next phase of development for ACU193.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2023
+0.6%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-6.1%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+35.9%
Q1 2023
Best reaction
-21.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.5% | -11.7% | — | |
| Q4 2025 | -2.3% | -10.3% | -2.3% | |
| Q3 2025 | -1.5% | -19.8% | +8.6% | |
| Q1 2025 | +0.0% | +1.9% | +8.6% | |
| Q4 2024 | +6.0% | -7.3% | -6.9% | |
| Q3 2024 | -21.4% | -25.5% | -35.7% | |
| Q2 2024 | -1.6% | +0.4% | -4.3% | |
| Q1 2024 | +13.1% | +8.6% | -21.4% | |
| Q4 2023 | -3.5% | +8.0% | -20.6% | |
| Q3 2023 | +12.1% | +20.0% | +53.2% | |
| Q2 2023 | -3.1% | +2.0% | -19.9% | |
| Q1 2023 | +35.9% | +15.5% | +0.4% | |
| Q4 2022 | +2.3% | +3.6% | -4.1% | |
| Q3 2022 | -5.1% | -10.6% | -15.3% | |
| Q2 2022 | +4.6% | -11.5% | +9.4% | |
| Q1 2022 | +9.6% | +4.5% | +7.8% | |
| Q4 2021 | -14.8% | -22.0% | -22.2% | |
| Q3 2021 | -17.1% | -23.9% | -46.7% | |
| Q2 2021 | +1.6% | +13.9% | +1.1% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro